drugset / Trial / NCT01816074

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children

NCT01816074

Phase 4 Completed 53 enrolled Seattle Children's Hospital Shire · collab
RandomizedCrossoverDouble-blindTreatment

Summary

We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may benefit most from multi-modal treatment

Timeline

Start
2012-10
Primary completion
2016-10
Completion
2017-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lisdexamfetamine Dimesylate Small molecule 70 mg